AAIC 2025 Abstract
Multiple Beneficial Effects of AR1001 on Aβ‐Induced Changes in Human Minibrain
Experiments in cellsInterventions
Abstract
Background: Human minibrain is an effective model for studying drug effects on neurodegenerative diseases like AD. AR1001, a phosphodiesterase‐5 (PDE5) inhibitor, is being tested in a global Phase 3 clinical trial for early AD at a dosage of 30 mg QD (NCT05531526). This study aims to evaluate effects of AR1001 in the minibrain model.
